Literature DB >> 6138267

Differential effects of the enantiomers of 3-(3-hydroxyphenyl)-N-n-propylpiperidine (3-PPP) at dopamine receptor sites.

S W Koch, B K Koe, N G Bacopoulos.   

Abstract

The agonist actions of 3-PPP at central dopamine (DA) autoreceptors were found to reside mostly in its (+) enantiomer, (+)-3-PPP also reduced striatal content of DOPAC and HVA, whereas (-)-3-PPP elevated HVA levels. Only (-)-3-PPP antagonized DA stimulation of DA-receptor linked adenylate cyclase. It was more effective than (+)-3-PPP at inhibiting [3H]DA binding to striatal membranes. The results suggest that (+)-3-PPP may act predominantly at DA autoreceptors, while (-)-3-PPP exhibits weak affinity for presynaptic and postsynaptic DA receptors.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138267     DOI: 10.1016/0014-2999(83)90299-6

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

1.  Is inhibition of striatal synaptosomal tyrosine hydroxylation by dopamine agonists a measure of dopamine autoreceptor function?

Authors:  C J Fowler; G Thorell; M Andersson; O Magnusson
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-10       Impact factor: 3.000

Review 2.  Dopamine-receptor agonists: mechanisms underlying autoreceptor selectivity. I. Review of the evidence.

Authors:  D Clark; S Hjorth; A Carlsson
Journal:  J Neural Transm       Date:  1985       Impact factor: 3.575

3.  BMY-14802 reverses the reduction of striatal dopamine release induced by (+)-3-[3-hydroxyphenyl]-N-(1-propyl)piperidine.

Authors:  A Kanzaki; K Okumura; H Ujike; K Tsuchida; K Akiyama; S Otsuki
Journal:  J Neural Transm Gen Sect       Date:  1992

4.  An electrophysiological analysis of the actions of the 3-PPP enantiomers on the nigrostriatal dopamine system.

Authors:  D Clark; G Engberg; E Pileblad; T H Svensson; A Carlsson; A S Freeman; B S Bunney
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-06       Impact factor: 3.000

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.